Joyce Liu, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

JoyceFuLiuMD

Oncology Boston, MA

Instructor in Medicine, Dana-Farber Cancer Institute

Dr. Liu is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Liu's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Hematology/Oncology, 2005 - 2008
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
  • Harvard Medical School
    Harvard Medical SchoolClass of 2002

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2004 - 2021
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian Cancer
    Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian CancerOctober 19th, 2019
  • OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STS
    OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STSNovember 29th, 2018
  • Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian Cancer
    Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian CancerJune 9th, 2017

Hospital Affiliations